Press Announcements > FDA authorizes first interoperable insulin pump intended to allow patients to customize treatment through their individual diabetes management devices

Press Announcements > FDA authorizes first interoperable insulin pump intended to allow patients to customize treatment through their individual diabetes management devices





FDA authorizes first interoperable insulin pump intended to allow patients to customize treatment through their individual diabetes management devices 

The U.S. Food and Drug Administration today permitted marketing of the Tandem Diabetes Care t:Slim X2 insulin pump with interoperable technology (interoperable t:Slim X2) for delivering insulin under the skin for children and adults with diabetes. This new type of insulin pump, referred to as an alternate controller enabled (ACE) infusion pump, or ACE insulin pump, is the first interoperable pump, meaning it can be used with different components that make up diabetes therapy systems, allowing patients to tailor their diabetes management to their individual device preferences. Diabetes therapy systems may be ...